Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.

Trial Profile

Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2012

At a glance

  • Drugs Telmisartan; Telmisartan/hydrochlorothiazide
  • Indications Cardiovascular disorders; Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 08 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top